SABSW
SAB Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.02
+0.43%Next report
Analyst consensus
- Next report date
- Nov 17, 2026
- EPS estimate
- -$0.27
- Revenue estimate
- $125.0K
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.28
- EPS estimate
- -$0.28
- Revenue actual
- —
- Revenue estimate
- $125.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +31.8%
- Revenue beats (12Q)
- —
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 17, 2026